The vast majority of patients with acute promyelocytic leukemia (APL, FAB M3) have the t(15;17)(q22;q21) chromosomal translocation (reviewed in Melnick and Licht 1 ). This introduces the gene for PML into the retinoic acid receptor a (RARA) locus, which leads to expression of a PML-RARA fusion. There is convincing evidence that expression of PML-RARA underlies the APL phenotype. 1 Yet, there have been rare cases of APL identified that do not manifest t(15;17). Many of these cases exhibit cryptic rearrangements of PML and RARA. 2 However, in a number of cases a fusion protein different from PML-RARA is expressed. The RARA gene has been consistently involved in these variant translocations. These include the t(11;17)(q23;q21) that expresses a PLZF-RARA fusion; t(5;17)(q35;q21) that encodes NPM-RARA; t(11;17)(q13;q21) that encodes NUMA-RARA; and der(17) with duplication of 17q21.3-q23 that fuses STAT5b to RARA (reviewed in Redner 3 ). These variant rearrangements are rare; fewer than 20 cases of the PLZF-RARA variant have been reported; only four cases of NPM-RARA; and one each of NUMA-RARA and STAT5b-RARA. Nevertheless, these variant translocations hold great importance as 'experiments of nature' and serve as tools to identify common biologic pathways that truly underlie development of the APL phenotype.
We here report a novel case of APL with fusion of RARA with a locus on 3p25. A 72-year-old man presented with a white blood cell count of 20.4 Â 10 9 /l, hemoglobin 10.3 g/l, and platelets 22 Â 10 9 /l. The peripheral blood white cell differential revealed 20% polymorphonuclear leukocytes, 4% bands, 15% lymphocytes, 19% monocytes, 34% blasts, 1% promyelocyte, 6% myelocytes, and 1% metamyelocytes. The majority of blasts demonstrated reniform or bilobed nuclear features. Auer rods were seen in many blasts along with prominent cytoplasmic granulation. The bone marrow biopsy was hypercellular (approximately 80%), with 88% blasts, 1.7% promyelocytes, 0.3% myelocytes, 0.3% polymorphonuclear leukocytes, 0.3% eosinophils, 3% monocytes, 0.3% pronormoblasts, 3.7% normoblasts, and 2.3% lymphocytes. The blasts were similar morphologically to those seen in the peripheral blood. The blasts were positive for chloroacetate esterase staining and were negative for staining with nonspecific esterase. Flow cytometry studies performed on the bone marrow showed the blasts to be positive for CD117, CD13 and/or CD33, partial CD15, CD33, and strongly myeloperoxidase positive. The blasts were negative for expression of CD34 and HLA-DR. The morphologic findings along with the flow cytometry results were consistent with a diagnosis of APL.
Cytogenetic studies indicated a mosaic abnormal chromosome pattern with an apparent normal cell line, represented by six cells, and one, represented by 14 cells, that demonstrated a 47,XY,t(3;17)(p25;q21), þ 8 karyotype (Figure 1 ). Analysis for PML-RARA expression by RT-PCR was indeterminate, owing to poor quality of the extracted RNA. FISH was therefore performed on two hundred unstimulated cells, primarily in interphase. FISH was carried out according to manufacturer instructions, using the Vysis LSI PML/RARA dual color single fusion and LSI RARA dual color break apart DNA probes (Downers Grove, IL). For identification of a partner chromosome, sequential FISH using the Vysis CEP3 DNA probe for the centromeric region of chromosome 3 was performed on the metaphase cells, previously hybridized with the LSI RARA DNA probe.
The PML/RARA probe, when hybridized to a cell containing t(15;17)(q22q21), is expected to result in a pattern of one yellow fusion signal on der(15)t(15;17), a red signal on normal chromosome 15 and a green signal on normal chromosome 17. In the case of an atypical translocation between chromosome 17 and a partner chromosome other than 15, the fusion signal will not be produced. In the current case, this test revealed 98.5% of the cells to be negative for PML-RARA rearrangement (the value of 1.5% positivity is within the Figure 2 FISH: Vysis (Downers Grove, Il) t(15;17) dual color DNA probe was used to determine PML-RARA rearrangement. Separate signals for PML and RARA were seen in both metaphase (a) and interphase spreads (b), indicating absence of PML-RARA fusion. The metaphase spread also indicates that one (green) signal for RARA is located on an A-group sized chromosome, consistent with this being chromosome 3. Metaphase (c) and interphase (d) cells were scored using the LSI RARA dual color DNA probe. 100% showed a split signal, indicating rearrangement of RARA and relocation of the green signal to an A-Group sized chromosome. The metaphase preparation (c) was sequentially hybridized using CEP probes for chromosomes 3 (red) and 17 (green) (e). Comparison of (c) and (e) indicate that the nonsplit RARA hybridzed to chromosome 17, and that the split RARA signal localizes to der (17) and der(3).
laboratory's control range for false positives), indicating that the partner chromosome is other than 15 (Figure 2a and b) . To confirm rearrangement of the RARA locus, 203 unstimulated cells were scored using the LSI RARA dual color DNA probe (Vysis). The RARA probe, when hybridized to a cell containing a translocation between 17q21 with involvement of the RARA gene and any partner chromosome, is expected to result in a pattern of one fusion signal for normal chromosome 17 and a split signal consisting of red signal on der(17) and green signal on a partner chromosome. 100% of the cells examined showed a split signal, indicating rearrangement of RARA (Figure 2c and  d) . Four metaphase cells each showed one fused yellow (red/ green) signal on the normal chromosome 17, one red signal on der (17), and one green signal on the distal arm of chromosome 3 (Figure 2c and d) , confirming the t(3;17) translocation observed by chromosome analysis of G-banded cells.
The patient expired before treatment could begin, apparently from a bleeding event. To determine whether the t(3;17) blasts could differentiate (a hallmark of t(15;17) APL 1 ), we obtained approval to use the excess clinical bone marrow aspirate for research from the University of Pittsburgh Committee on Oversight of Research Involving the Dead. Mononuclear cells were separated over a ficoll gradient (Histopaque, Sigma, St. Louis, MO) and incubated at 371C, 5% CO 2 in RMPI 1640 (Cellgrow; Mediatech, Herndon, VA) supplemented with glutamine, pen/strep, and 10% Fetal Bovine Serum (Gibco, Invitrogen, Carlsbad, CA). ATRA (Sigma) (1 mM) or vehicle control were added to duplicate cultures. After 10 days in culture, cytospins were prepared using a Shandon Cytospin 4 Cytocentrifuge (Thermo Electronics, Pittsburgh, PA) and stained with Wright's/Giemsa stain. Cell counts and differential were performed manually. 58% of the cells resembled metamyelocytes, bands, or mature polymorphonuclear leukocytes (Figure 3) , compared with none in the vehicle control culture. This is the first description of a case of APL with a t(3;17) variant translocation. This patient demonstrated the mild leukocytosis, bleeding tendency, and immunophenotype typical for t(15;17) APL. Like t(15;17) and the other variants that have been analyzed on a molecular level, t(3;17) also disrupts the locus for the retinoic acid receptor a, indicating the critical status of this gene in the pathogenesis of APL. The PML gene was not involved in this rearrangement. Similar to the t(15;17), t(5;17), and t(11;17)(q13;q21) variants, the cells derived from t(3;17) differentiate in the presence of ATRA, a hallmark of APL. 1 Efforts are ongoing to identify the fusion partner for RARA in this case of t(3;17). Deletion of 3p25 is a frequent site for loss of heterozygosity in lung cancer, 4 breast cancer 5 head and neck cancer, 6 and renal cancer. 7 In all, 104 genes have been mapped to the 3p25 locus (the full list can be accessed at http:// www.ncbi.nlm.nih.gov/mapview/maps.cgi?TAXID ¼ 9606&CHR ¼ 3&MAPS ¼ cntg-r,comp,sts,genec[408.00%3A963.00]-r&CMD ¼ TXT#1). Within this region are located the DNA repair gene hOGGI, deletions of which have been linked to bladder cancer, 7 and the von Hippel-Lindau tumor suppressor. 8 It will be interesting to see if the putative RARA fusion protein expressed in t(3;17) conforms to current hypotheses and paradigms for the molecular pathogenesis of APL. Hairy cell leukemia is a rare indolent lymphoproliferative malignancy characterized by splenomegaly and pancytopenia. Patients are prone to acquire life-threatening infections and can develop mycobacterial diseases. 1 Traditional tools for tuberculosis diagnosis rely on the identification of mycobacteria through microscopy and culture. These methods have low sensitivity and so cannot usefully rule out a diagnosis of tuberculosis where this is suspected. Moreover, mycobacterial culture can take several weeks, often delaying diagnosis and initiation of therapy. As a result, a significant proportion of tuberculosis patients are diagnosed only at autopsy. This diagnostic delay, and its adverse consequences, are even greater in immunosuppressed patients in whom the clinical presentation is frequently nonspecific and the progression of tuberculosis is more rapid.
The tuberculin skin test (TST) confirms infection and not active disease, but in low burden countries (where the prevalence of latent tuberculosis infection in the general population is low), a positive TST result can help in the decision to start treatment while mycobacterial culture results are awaited, or support a clinical diagnosis of tuberculosis when bacteriological confirmation is lacking. Conversely, a negative result might, in theory, help to rule out a diagnosis of tuberculosis. However, the TST is of little help in immunosuppressed patients, such as those with hematological malignancies, who often have falsely negative TST results. 2 A test of Mycobacterium tuberculosis infection with high diagnostic sensitivity would therefore be useful in the evaluation of immunosuppressed patients where tuberculosis is included in the differential diagnosis. The ex vivo enzyme-linked immunospot (ELISPOT) assay is a very sensitive method for detecting low frequencies of antigen-specific interferon-g-producing T cells direct from peripheral blood. Thus, it may provide a more sensitive means of detecting M. tuberculosis-specific immune responses than the TST, which measures cutaneous delayed-type hypersensitivity to purified protein derivative (PPD). Two M. tuberculosis gene products, early secretory antigen target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10), are strong targets of cellular immune response in tuberculosis patients and contacts. 3 Recently, the ELISPOT-RD1 assay for interferon-g-producing T-cells specific for ESAT-6 or CFP-10 peptides, has been demonstrated to be a rapid, highly sensitive and specific diagnostic tool for the detection of M. tuberculosis infection, including in immunosuppressed individuals. [4] [5] [6] Here, we describe how the ELISPOT-RD1 accelerated the diagnosis of disseminated tuberculosis in a leukemic patient with persistent fever and a negative TST.
A 68-year-old Caucasian woman presented with fatigue, weight loss, night sweats and fever. Her medical history revealed that her mother died of tuberculous osteomyelitis. Physical examination showed splenomegaly, without peripheral lymphadenopathy. The peripheral blood count showed hemoglobin 9.0 g/dl, white blood cells 2.2 Â 10 9 /l and platelet count 69 Â 10 9 /l. A bone marrow biopsy revealed 90% of cells expressing CD20, CD25, CD11c and CD103, consistent with a diagnosis of hairy cell leukemia. An abdominal computed tomography (CT) scan confirmed the splenomegaly, with multiple hypodense lesions. A chest radiogram was normal. Therefore, the patient was treated with interferon-a2b, 2 Â 10 6 /m 2 IU three times a week. After 2 months, she was readmitted to the hospital for persistent fever. Despite improvement in the blood count, an abdominal CT scan showed the splenic lesions to be unchanged. Chest CT scan revealed minimal bilateral pleural effusions. At that time, interferon therapy was withdrawn. The day after admission, samples from blood, urine, faeces and pleural fluid were obtained for microbiologic examination. The following day the patient underwent bronchoscopy with bronchoalveolar lavage (BAL). TST was negative (induration 1 mm after 72 h, using 5 IU of PPD). At 1 week after admission, despite step-wise usage of empirical antimicrobial treatment the fever persisted and the patient's condition worsened (Figure 1a) . All tests for mycobacterial, bacterial, fungal and viral pathogens were negative. Similarly, microscopic examination for acid-fast bacilli was negative. Pleural fluid microscopy yielded an inflammatory effusion with a prevalence of neutrophils together with a small number of macrophages, lymphocytes and activated mesothelial cells (Figure 1b) . Recognising the possibility that the TST result in this immunosuppressed patient might be falsely negative, we performed an ex vivo ELISPOT-RD1 test on blood, as previously described.
